U.S., Oct. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07863180) titled 'Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial' on Oct. 01.
Brief Summary: This research is studying a supplement called tributyrin in people with Progressive Supranuclear Palsy (PSP) to learn about its safety and tolerability as a potential treatment. The goal of this research study is to see if a similar supplementation regimen and virtual testing is feasible for people with PSP.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Parkinson Disease
Multiple System Atrophy
Progressive Supranuclear Palsy(PSP)
Intervention:
DRUG: Tributyrin
Post-biotic short chain fatty acid dietary supplemen...